Bingfang Yan

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 6

Top Topics

Genetic Diversity

Drug Administration

Respiratory Syndrome Coronavirus

Top Venues

Fundamental & clinical pharmacology

Drug metabolism and disposition: the biological fate of chemicals

Hepatology communications

Animal diseases

This page only lists publications with an associated author ORCID identifier.

Publications

Daisy Yan, Bingfang Yan
Viral target and metabolism-based rationale for combined use of recently authorized small molecule COVID-19 medicines: Molnupiravir, nirmatrelvir, and remdesivir. Fundamental & clinical pharmacology (2023)
Daisy Yan, Bingfang Yan
Viral target- and metabolism-based rationale for combined use of recently authorized small molecule COVID-19 medicines: molnupiravir, nirmatrelvir and remdesivir. Fundamental & clinical pharmacology (2023)
Yue Shen, William Eades, William Liu, Bingfang Yan
The COVID-19 Oral Drug Molnupiravir Is a CES2 Substrate: Potential Drug-Drug Interactions and Impact of CES2 Genetic Polymorphism In Vitro. Drug metabolism and disposition: the biological fate of chemicals 50 (9) (2022)
Yue Shen, William Eades, Bingfang Yan
The COVID-19 Medicine Remdesivir Is Therapeutically Activated by Carboxylesterase-1, and Excessive Hydrolysis Increases Cytotoxicity. Hepatology communications 5 (9) (2021)
Daisy Yan, One Hyuk Ra, Bingfang Yan
The nucleoside antiviral prodrug remdesivir in treating COVID-19 and beyond with interspecies significance. Animal diseases 1 (1) (2021)
Yue Shen, William Eades, Bingfang Yan
Remdesivir potently inhibits carboxylesterase-2 through covalent modifications: signifying strong drug-drug interactions. Fundamental & clinical pharmacology 35 (2) (2021)